The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drug Repositioning Market Research Report 2024
Synopsis
Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.
The global Drug Repositioning market was valued at US$ 26270 million in 2023 and is anticipated to reach US$ 36370 million by 2030, witnessing a CAGR of 4.7% during the forecast period 2024-2030.
Global Drug Repositioning key players include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, etc. Global top five manufacturers hold a share about 15%.
North America is the largest market, with a share about 40%, followed by Europe and China, both have a share over 30 percent.
In terms of product, Generic Drugs is the largest segment, with a share about 65%. And in terms of application, the largest application is Cancer, followed by Cardiovascular Diseases.
This report aims to provide a comprehensive presentation of the global market for Drug Repositioning, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Repositioning.
Report Scope
The Drug Repositioning market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drug Repositioning market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drug Repositioning companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Segment by Type
Generic Drugs
Clinical Trial Failed Drugs
Segment by Application
Cardiovascular Diseases
Mental Illness
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Repositioning companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.
The global Drug Repositioning market was valued at US$ 26270 million in 2023 and is anticipated to reach US$ 36370 million by 2030, witnessing a CAGR of 4.7% during the forecast period 2024-2030.
Global Drug Repositioning key players include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, etc. Global top five manufacturers hold a share about 15%.
North America is the largest market, with a share about 40%, followed by Europe and China, both have a share over 30 percent.
In terms of product, Generic Drugs is the largest segment, with a share about 65%. And in terms of application, the largest application is Cancer, followed by Cardiovascular Diseases.
This report aims to provide a comprehensive presentation of the global market for Drug Repositioning, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drug Repositioning.
Report Scope
The Drug Repositioning market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drug Repositioning market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drug Repositioning companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Segment by Type
Generic Drugs
Clinical Trial Failed Drugs
Segment by Application
Cardiovascular Diseases
Mental Illness
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Repositioning companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drug Repositioning Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Generic Drugs
1.2.3 Clinical Trial Failed Drugs
1.3 Market by Application
1.3.1 Global Drug Repositioning Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cardiovascular Diseases
1.3.3 Mental Illness
1.3.4 Cancer
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug Repositioning Market Perspective (2019-2030)
2.2 Drug Repositioning Growth Trends by Region
2.2.1 Global Drug Repositioning Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drug Repositioning Historic Market Size by Region (2019-2024)
2.2.3 Drug Repositioning Forecasted Market Size by Region (2025-2030)
2.3 Drug Repositioning Market Dynamics
2.3.1 Drug Repositioning Industry Trends
2.3.2 Drug Repositioning Market Drivers
2.3.3 Drug Repositioning Market Challenges
2.3.4 Drug Repositioning Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug Repositioning Players by Revenue
3.1.1 Global Top Drug Repositioning Players by Revenue (2019-2024)
3.1.2 Global Drug Repositioning Revenue Market Share by Players (2019-2024)
3.2 Global Drug Repositioning Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drug Repositioning Revenue
3.4 Global Drug Repositioning Market Concentration Ratio
3.4.1 Global Drug Repositioning Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug Repositioning Revenue in 2023
3.5 Drug Repositioning Key Players Head office and Area Served
3.6 Key Players Drug Repositioning Product Solution and Service
3.7 Date of Enter into Drug Repositioning Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug Repositioning Breakdown Data by Type
4.1 Global Drug Repositioning Historic Market Size by Type (2019-2024)
4.2 Global Drug Repositioning Forecasted Market Size by Type (2025-2030)
5 Drug Repositioning Breakdown Data by Application
5.1 Global Drug Repositioning Historic Market Size by Application (2019-2024)
5.2 Global Drug Repositioning Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drug Repositioning Market Size (2019-2030)
6.2 North America Drug Repositioning Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drug Repositioning Market Size by Country (2019-2024)
6.4 North America Drug Repositioning Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drug Repositioning Market Size (2019-2030)
7.2 Europe Drug Repositioning Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drug Repositioning Market Size by Country (2019-2024)
7.4 Europe Drug Repositioning Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug Repositioning Market Size (2019-2030)
8.2 Asia-Pacific Drug Repositioning Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drug Repositioning Market Size by Region (2019-2024)
8.4 Asia-Pacific Drug Repositioning Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drug Repositioning Market Size (2019-2030)
9.2 Latin America Drug Repositioning Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drug Repositioning Market Size by Country (2019-2024)
9.4 Latin America Drug Repositioning Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug Repositioning Market Size (2019-2030)
10.2 Middle East & Africa Drug Repositioning Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drug Repositioning Market Size by Country (2019-2024)
10.4 Middle East & Africa Drug Repositioning Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Drug Repositioning Introduction
11.1.4 Teva Revenue in Drug Repositioning Business (2019-2024)
11.1.5 Teva Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Drug Repositioning Introduction
11.2.4 Novartis Revenue in Drug Repositioning Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Mylan
11.3.1 Mylan Company Detail
11.3.2 Mylan Business Overview
11.3.3 Mylan Drug Repositioning Introduction
11.3.4 Mylan Revenue in Drug Repositioning Business (2019-2024)
11.3.5 Mylan Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Drug Repositioning Introduction
11.4.4 Johnson & Johnson Revenue in Drug Repositioning Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Drug Repositioning Introduction
11.5.4 Pfizer Revenue in Drug Repositioning Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Bausch Health
11.6.1 Bausch Health Company Detail
11.6.2 Bausch Health Business Overview
11.6.3 Bausch Health Drug Repositioning Introduction
11.6.4 Bausch Health Revenue in Drug Repositioning Business (2019-2024)
11.6.5 Bausch Health Recent Development
11.7 GSK
11.7.1 GSK Company Detail
11.7.2 GSK Business Overview
11.7.3 GSK Drug Repositioning Introduction
11.7.4 GSK Revenue in Drug Repositioning Business (2019-2024)
11.7.5 GSK Recent Development
11.8 ChemRar Group
11.8.1 ChemRar Group Company Detail
11.8.2 ChemRar Group Business Overview
11.8.3 ChemRar Group Drug Repositioning Introduction
11.8.4 ChemRar Group Revenue in Drug Repositioning Business (2019-2024)
11.8.5 ChemRar Group Recent Development
11.9 Glenmark
11.9.1 Glenmark Company Detail
11.9.2 Glenmark Business Overview
11.9.3 Glenmark Drug Repositioning Introduction
11.9.4 Glenmark Revenue in Drug Repositioning Business (2019-2024)
11.9.5 Glenmark Recent Development
11.10 Fujifilm
11.10.1 Fujifilm Company Detail
11.10.2 Fujifilm Business Overview
11.10.3 Fujifilm Drug Repositioning Introduction
11.10.4 Fujifilm Revenue in Drug Repositioning Business (2019-2024)
11.10.5 Fujifilm Recent Development
11.11 Dr. Reddy
11.11.1 Dr. Reddy Company Detail
11.11.2 Dr. Reddy Business Overview
11.11.3 Dr. Reddy Drug Repositioning Introduction
11.11.4 Dr. Reddy Revenue in Drug Repositioning Business (2019-2024)
11.11.5 Dr. Reddy Recent Development
11.12 R-Pharma
11.12.1 R-Pharma Company Detail
11.12.2 R-Pharma Business Overview
11.12.3 R-Pharma Drug Repositioning Introduction
11.12.4 R-Pharma Revenue in Drug Repositioning Business (2019-2024)
11.12.5 R-Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
